Cerebriu

Cerebriu operates at the intersection of radiology AI, medical-device software, and MRI workflow automation. Its differentiation is architectural: Apollo is intended to support decisions during scan acquisition through real-time detection and adaptive protocol changes, as well as after acquisition through interpretation and worklist prioritization. Many radiology AI products primarily analyze completed studies, so Cerebriu’s acquisition-stage focus gives it a distinct workflow position, although it also creates higher integration, validation, and regulatory requirements. Apollo Brain is described as a CE-marked Class IIa device under MDR 2017/745, and the Siemens Healthineers relationship gives Cerebriu an OEM integration pathway into a substantial MRI installed base. The company serves hospitals, private radiology centers, stroke centers, and teleradiology providers, expanding its addressable market beyond a single clinical setting. Cerebriu’s market position is therefore best characterized as a specialized, acquisition-focused neuroimaging platform rather than a broad, modality-agnostic radiology AI vendor.

Cerebriu’s trajectory shows a shift from early non-dilutive and structured financing toward larger institutional rounds and commercial deployment. Its disclosed history includes grants, a $0.52 million debt financing round, and convertible notes in 2020-2022, followed by a €17.4 million Series A announced on Sep 12, 2024. The €9.4 million financing announced on Sep 18, 2025 represents the next major capital inflection point and raised cumulative recorded funding to approximately $35.97 million. Product development also appears to have progressed from individual Apollo capabilities—Smart Protocol, Smart Reading, and Smart Priority—to an OEM-embedded offering with Siemens Healthineers. The CE-mark milestone reported on Sep 19, 2025 supports a transition from technical development toward regulated commercial deployment.